Melioidosis

类鼻疽

Evidence-backed information EN 5/7 applicable sections · ZH 5/7 applicable sections Updated Oct 23, 2026

Melioidosis is a life-threatening bacterial infection caused by the Gram-negative environmental pathogen Burkholderia pseudomallei, which thrives in soil and water across tropical and subtropical regions ^[1]^[2]. Global modelled estimates indicate an annual burden of up to 165,000 cases and approximately 89,000 deaths, with incidence frequently correlating with heavy rainfall and severe weather events ^[1]^[3]. Human acquisition typically follows direct environmental exposure through skin penetration, inhalation, or ingestion, particularly among individuals with underlying metabolic or immune conditions ^[2]^[4].

Read the full clinical and epidemiological profile 6

Definition

Melioidosis is classified as a bacterial infectious disease caused by Burkholderia pseudomallei, a metabolically adaptable Gram-negative organism recognized as a tier 1 select agent ^[1]^[5]. The pathogen primarily resides within soil and aquatic environments in tropical climates, functioning as a facultative intracellular bacterium capable of manipulating host immune responses to ensure survival ^[2]. Clinically, the condition encompasses a broad spectrum ranging from asymptomatic colonization to acute fulminant sepsis and chronic granulomatous infections that may persist for extended durations ^[2]^[4].

Clinical features

Clinical manifestations vary widely depending on the route of inoculation, bacterial load, and host immune status, ranging from localized cutaneous lesions to acute bacteremic pneumonia and disseminated visceral abscesses ^[1]^[2]. A significant proportion of patients initially present with sepsis, while approximately ten percent progress to chronic melioidosis characterized by symptoms lasting longer than two months, including persistent fever, weight loss, and productive coughs that may mimic tuberculosis ^[2]^[4]. Long-standing multi-site abscesses and pulmonary involvement without typical scarring or calcification further distinguish the chronic presentation from other respiratory diseases ^[4].

Epidemiology

The disease demonstrates a pronounced geographic concentration in Southeast Asia and northern Australia, with increasing worldwide reports attributed to expanding environmental reservoirs and climate-related weather patterns ^[1]^[3]. Modelled data indicate substantial global under-reporting, prompting calls for formal recognition as a neglected tropical disease due to its estimated annual mortality exceeding 89,000 fatalities ^[3]. Case clusters frequently correlate with periods of intense rainfall, flooding, and agricultural or environmental disturbances, suggesting strong ecological drivers for sporadic outbreaks ^[1]^[3]. Additionally, temperate nations predominantly experience imported cases, highlighting travel and migration as key factors in non-endemic surveillance landscapes ^[4].

Transmission

Primary human acquisition occurs through direct environmental contact with contaminated soil or water, facilitating pathogen entry via dermal abrasions, inhalation of aerosolized particles, or ingestion of tainted materials ^[2]^[4]. Direct person-to-person or animal-to-human spread is exceptionally rare, underscoring the strictly sapronotic nature of the infection cycle ^[4]. The bacterium’s capacity for prolonged environmental persistence and facultative intracellular survival enables continuous community exposure in endemic zones without requiring intermediate hosts ^[2].

Prevention

Public health strategies emphasize minimizing direct contact with potentially contaminated soil and surface waters, particularly during heavy rainfall or flooding events in endemic regions ^[1]^[3]. Community-based awareness initiatives and targeted educational campaigns have been implemented in high-burden areas to improve recognition of early symptoms and reduce delayed healthcare seeking ^[4]. While specific prophylactic interventions remain limited, ongoing research into vaccine development has advanced several candidates to early-phase clinical evaluation, reflecting growing efforts to mitigate future population-level risk ^[1]^[3].

References

1 Gassiep I et al. Human Melioidosis. Clin Microbiol Rev. 2020 Mar 18. PMID: 32161067. doi: 10.1128/CMR.00006-19. PubMed: https://pubmed.ncbi.nlm.nih.gov/32161067/
2 Wiersinga WJ et al. Melioidosis. Nat Rev Dis Primers. 2018 Feb 1. PMID: 29388572. doi: 10.1038/nrdp.2017.107. PubMed: https://pubmed.ncbi.nlm.nih.gov/29388572/
3 Meumann EM et al. Burkholderia pseudomallei and melioidosis. Nat Rev Microbiol. 2024 Mar. PMID: 37794173. doi: 10.1038/s41579-023-00972-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/37794173/
4 Wikipedia contributors. Melioidosis - Wikipedia [Internet]. Wikipedia. cited 3 Sept 2026. Available from: https://en.wikipedia.org/wiki/Melioidosis
5 Rhodes KA et al. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016 Sep. PMID: 27620956. doi: 10.1016/j.drup.2016.07.003. PubMed: https://pubmed.ncbi.nlm.nih.gov/27620956/